Dai-Ichi Karkaria Q2 Results: Consolidated Profit Grows to Rs 0.90 Crore

CHEMICALS
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Dai-Ichi Karkaria Q2 Results: Consolidated Profit Grows to Rs 0.90 Crore

Dai-Ichi Karkaria Limited reported revenue growth for the quarter ending September 30, 2026, reaching Rs 54.11 crore compared to Rs 42.79 crore in the same period last year. While the standalone results showed a minor net loss of Rs 0.35 crore, the consolidated performance turned profitable at Rs 0.90 crore. The specialty chemicals manufacturer continues to focus on its singular operational segment as it scales revenue significantly on a year-on-year basis for the first half of the fiscal year.

Dai-Ichi Karkaria Q2 Revenue Jumps on Strong Performance

Revenue for the quarter reached Rs 54.11 crore, with consolidated profit climbing to Rs 0.90 crore.

Reader Takeaway: Revenue expansion highlights operational growth, though the company continues to manage mixed bottom-line results across segments.

What just happened

Dai-Ichi Karkaria Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant increase in revenue from operations to Rs 54.11 crore for the September quarter, up from Rs 42.79 crore in the corresponding period of the previous year. For the half-year period, revenues rose to Rs 111.95 crore from Rs 82.24 crore.

Why this matters

The company achieved a consolidated profit of Rs 0.90 crore for the quarter, marking an improvement over the nominal profit of Rs 0.01 crore reported in Q2 of the previous year. While standalone performance recorded a minor net loss of Rs 0.35 crore, the overall consolidated trajectory reflects a recovery and expansion in the specialty chemicals segment.

What changes now

The Board of Directors approved these results on October 30, 2026, following a review by the Audit Committee. The company maintains its focus on the Specialty Chemicals sector as its sole reportable business segment, simplifying its operational reporting structure for shareholders. Statutory auditors have provided an unmodified opinion on the limited review, ensuring transparency in financial reporting.

What to track next

Investors should monitor the company's ability to maintain its revenue growth momentum while improving standalone profitability margins in the upcoming quarters. Further expansion in the specialty chemicals market remains a primary driver for the company's long-term financial health.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.